Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.

From molecule to the medicine cabinet

Our scientific subsidiary, Forest Research Institute, Inc. (FRI), drives the development of our novel pharmaceutical agents and provides medical and scientific support for currently marketed products.

The growth of Forest as a company is driven by our R&D productivity. By having steadily increased our R&D investment and deepened our pool of talent over the past decade, Forest has strengthened its ability to license innovative new products earlier in the development cycle and across a wider span of therapeutic areas. Once a compound enters our pipeline, we collaborate closely with our partner to formulate and implement a development plan that will maximize the potential benefits of the drug.

Read further to learn more about our R&D pipeline.

Please click here to learn about our Post Marketing Commitments.


Please click here if you are interested in information on being a Forest clinical trial investigator.

If you are interested in obtaining information on our Investigator Initiated Trials (IIT) program, click here.

Forest was rated among the top 3 biopharmaceutical companies to work with in a 2013 Global Investigative Site Relationship survey.


We credit our success in bringing important new products to market on two key strengths. First, we have a proven track record of identifying and licensing innovative compounds. Second, our comprehensive research, development, and regulatory capabilities enable us to address the requisite tasks for each of our drug candidates and rapidly advance our clinical pipeline.

Marco Taglietti, M.D. Executive Vice President, Drug Development
and Research, and Chief Medical Officer